Sabra Health Care REIT, Inc. (SBRA) Key Metrics
SBRA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $4.94B
- Enterprise value
- $7.44B
- P/E (TTM)
- 77.4 10-yr median 27.9
- Forward P/E
- 32.2
- PEG ratio
- 5.28
- Price / sales
- 5.7 10-yr median 5.5
- Price / book
- 1.8 10-yr median 1.1
- EV / EBITDA
- 18.9 10-yr median 15.6
- Dividend yield
- 6.20% $1.20 a year
- Beta
- 0.62
SBRA key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSBRA valuation Price multiples at each fiscal year-end price.
SBRA returns How much profit the business earns on the capital it uses.
SBRA per-share figures Results divided by the shares outstanding at year-end.
SBRA financial health Debt, liquidity and how easily interest is covered.
SBRA efficiency & capital use Working capital cycle and where the cash goes.
SBRA valuation history
SBRA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SBRA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SBRA cash returned to shareholders
SBRA price vs earnings per share
SBRA key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $4.63B | $4.09B | $3.32B | $2.87B | $2.97B | $3.60B | $4.01B | $2.95B | $1.99B | $1.60B |
| Enterprise value | $7.11B | $6.47B | $5.73B | $5.37B | $7.03B | $7.22B | $6.46B | $6.13B | $4.86B | $2.79B |
| P/E ratio | 29.8 | 32.3 | 241.5 | — | — | 26.0 | 58.2 | 10.6 | 12.5 | 22.8 |
| Price / sales | 6.0 | 5.8 | 5.1 | 4.6 | 5.2 | 6.0 | 6.0 | 4.7 | 4.9 | 6.1 |
| Price / book | 1.6 | 1.5 | 1.2 | 0.9 | 0.9 | 1.1 | 1.2 | 0.9 | 0.6 | 1.6 |
| Price / free cash flow | 13.3 | 13.2 | 11.1 | 9.1 | 9.2 | 14.4 | 10.8 | 6.5 | — | 9.1 |
| Price / operating cash flow | 13.3 | 13.2 | 11.1 | 9.1 | 8.3 | 10.1 | 10.8 | 8.2 | 14.9 | 9.1 |
| EV / sales | 9.2 | 9.2 | 8.8 | 8.6 | 12.3 | 12.1 | 9.7 | 9.8 | 12.0 | 10.7 |
| EV / EBITDA | 15.6 | 15.7 | 18.4 | 24.8 | 42.3 | 17.3 | 12.3 | 12.0 | 13.7 | 9.8 |
| EV / free cash flow | 20.4 | 20.8 | 19.1 | 17.0 | 21.8 | 29.0 | 17.3 | 13.6 | — | 15.8 |
| Earnings yield | 3.4% | 3.1% | 0.4% | −2.7% | −3.8% | 3.8% | 1.7% | 9.5% | 8.0% | 4.4% |
| Free cash flow yield | 7.5% | 7.6% | 9.0% | 11.0% | 10.9% | 6.9% | 9.3% | 15.3% | −10.1% | 11.0% |
| Dividend yield | 6.3% | 6.9% | 8.4% | 9.7% | 8.9% | 7.7% | 8.4% | 11.0% | 9.2% | 7.5% |
| Shareholder yield (dividends + buybacks) | 6.3% | 6.9% | 8.4% | 9.8% | 19.3% | 10.0% | 22.0% | 15.9% | 9.2% | 7.5% |
| Share price at fiscal year-end | $18.94 | $17.32 | $14.27 | $12.43 | $13.54 | $17.37 | $21.34 | $16.48 | $18.77 | $24.42 |
| Per share | ||||||||||
| Revenue per share | $3.17 | $2.98 | $2.78 | $2.71 | $2.60 | $2.89 | $3.55 | $3.49 | $3.83 | $3.98 |
| Earnings per share | $0.64 | $0.54 | $0.06 | −$0.34 | −$0.52 | $0.67 | $0.37 | $1.56 | $1.50 | $1.07 |
| Operating cash flow per share | $1.43 | $1.32 | $1.29 | $1.37 | $1.63 | $1.71 | $1.98 | $2.01 | $1.26 | $2.70 |
| Free cash flow per share | $1.43 | $1.32 | $1.29 | $1.37 | $1.47 | $1.20 | $1.98 | $2.53 | −$1.90 | $2.70 |
| Cash per share | $0.29 | $0.26 | $0.18 | $0.21 | $0.51 | $0.29 | $0.21 | $0.28 | $4.90 | $0.39 |
| Book value per share | $11.54 | $11.61 | $12.04 | $13.23 | $15.43 | $16.45 | $18.54 | $18.19 | $32.43 | $15.50 |
| Tangible book value per share | $11.27 | $11.50 | $11.91 | $13.06 | $15.18 | $15.65 | $17.46 | $16.72 | $29.28 | $15.10 |
| Dividends per share | $1.18 | $1.19 | $1.19 | $1.20 | $1.20 | $1.34 | $1.78 | $1.82 | $1.72 | $1.82 |
| Capex per share | $0.00 | $0.00 | $0.02 | $0.64 | $0.15 | $0.51 | $1.34 | $0.52 | $3.16 | $0.86 |
| Debt per share | $10.43 | $10.36 | $10.51 | $11.04 | $19.07 | $17.75 | $13.19 | $18.08 | $32.07 | $18.48 |
| Shares outstanding | 244.5M | 236.0M | 232.8M | 230.9M | 219.1M | 207.3M | 188.1M | 178.7M | 105.8M | 65.5M |
| Change in shares outstanding | +3.6% | +1.4% | +0.8% | +5.4% | +5.7% | +10.2% | +5.3% | +68.9% | +61.5% | +4.9% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 5.6% | 4.6% | 0.5% | −2.4% | −3.3% | 4.0% | 2.0% | 8.4% | 7.1% | 6.8% |
| Return on invested capital (ROIC) | 5.0% | 4.9% | 3.6% | 2.9% | 2.3% | 3.7% | 8.1% | 4.8% | 5.3% | 3.5% |
| Return on assets (ROA) | 2.9% | 2.4% | 0.2% | −1.3% | −1.9% | 2.3% | 1.1% | 4.1% | 3.4% | 3.0% |
| Return on tangible assets | 2.9% | 2.4% | 0.3% | −1.4% | −1.9% | 2.4% | 1.2% | 4.4% | 2.4% | 3.1% |
| Free cash flow margin | 45.0% | 44.2% | 46.4% | 50.5% | 56.7% | 41.6% | 55.7% | 72.5% | −49.5% | 67.8% |
| Income quality (OCF / net income) | 2.24 | 2.45 | 21.85 | — | — | 2.56 | 5.40 | 1.28 | 0.84 | 2.51 |
| Financial health | ||||||||||
| Total debt | $2.55B | $2.44B | $2.45B | $2.55B | $4.18B | $3.68B | $2.48B | $3.23B | $3.39B | $1.21B |
| Cash & short-term investments | $71.5M | $60.5M | $41.3M | $49.3M | $112.0M | $59.1M | $39.1M | $50.2M | $518.6M | $25.7M |
| Net debt | $2.48B | $2.38B | $2.41B | $2.50B | $4.07B | $3.62B | $2.44B | $3.18B | $2.88B | $1.19B |
| Debt / equity | 0.90 | 0.89 | 0.87 | 0.83 | 1.24 | 1.08 | 0.71 | 0.99 | 0.99 | 1.19 |
| Debt / assets | 0.46 | 0.46 | 0.45 | 0.44 | 0.70 | 0.61 | 0.41 | 0.48 | 0.48 | 0.53 |
| Net debt / EBITDA | 5.43 | 5.78 | 7.71 | 11.53 | 24.46 | 8.69 | 4.63 | 6.22 | 8.13 | 4.15 |
| Current ratio | 0.56 | 0.88 | 0.78 | 0.59 | 4.57 | 2.25 | 2.41 | 3.12 | 8.02 | 4.66 |
| Quick ratio | 0.56 | 0.88 | 0.58 | −0.62 | 3.73 | 1.76 | 1.87 | 3.12 | 8.02 | 4.66 |
| Interest coverage | 2.3 | 2.2 | 2.0 | 2.2 | 2.1 | 2.4 | 4.2 | 2.1 | 2.5 | 2.5 |
| Working capital | −$147.5M | −$26.4M | −$50.9M | −$137.4M | $510.1M | $182.7M | $153.9M | $201.5M | $719.7M | $144.9M |
| Invested capital | $5.30B | $5.13B | $5.21B | $5.56B | $7.45B | $7.03B | $5.93B | $6.43B | $6.31B | $2.20B |
| Tangible asset value | $2.76B | $2.71B | $2.77B | $3.02B | $3.33B | $3.24B | $3.29B | $2.99B | $3.10B | $989.4M |
| Net current asset value | −$2.48B | −$2.36B | −$2.40B | −$2.49B | −$1.93B | −$2.25B | −$2.32B | −$3.11B | −$2.77B | −$1.07B |
| Graham number | $12.86 | $11.84 | $4.00 | — | — | $15.72 | $12.37 | $25.28 | $33.05 | $19.34 |
| Graham net-net per share | −$10.28 | −$10.18 | −$10.39 | −$10.07 | −$9.19 | −$11.02 | −$12.50 | −$17.81 | −$27.40 | −$16.98 |
| Capital allocation | ||||||||||
| Dividends paid | $289.5M | $280.1M | $277.4M | $277.2M | $262.9M | $278.3M | $335.4M | $325.2M | $182.1M | $119.3M |
| Share buybacks (net) | — | — | $2.7M | $4.8M | $308.7M | $80.1M | $549.3M | $143.8M | $0 | $1.3M |
| Dividend payout ratio | 186.0% | 221.1% | — | — | — | 201.1% | 486.2% | 116.5% | 115.0% | 169.7% |
| Dividends + buybacks / free cash flow | 83.0% | 90.2% | 93.2% | 89.3% | 177.1% | 143.8% | 237.5% | 103.8% | — | 68.2% |
| Capex / revenue | 0.0% | 0.0% | 0.8% | 23.5% | 5.9% | 17.6% | 37.8% | 15.0% | 82.4% | 21.7% |
| Capex / operating cash flow | 0.0% | 0.0% | 1.7% | 46.5% | 9.4% | 29.8% | 67.8% | 26.0% | 250.3% | 32.0% |
| Capex / depreciation | 0.00 | 0.00 | 0.03 | 0.78 | 0.19 | 0.60 | 1.39 | 0.47 | 2.96 | 0.83 |
| Stock-based compensation / revenue | 1.5% | 1.3% | 1.2% | 1.2% | 1.4% | 1.3% | 1.5% | 1.2% | 2.1% | 2.9% |
| R&D / revenue | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| SG&A / revenue | 6.9% | 7.1% | 7.3% | 6.3% | 6.1% | 5.5% | 4.6% | 5.8% | 8.0% | 7.6% |
| Efficiency | ||||||||||
| Days sales outstanding | 57.3 | 68.9 | 79.4 | 200.1 | 256.6 | 145.4 | 122.9 | 138.0 | 173.1 | 294.3 |
| Days of inventory on hand | — | — | 428.2 | 596.1 | 247.8 | 182.0 | 196.9 | — | — | — |
| Days payables outstanding | — | 113.8 | 201.9 | 320.1 | 373.9 | 307.5 | 283.1 | 726.9 | 1,452.7 | 2,394.3 |
| Cash conversion cycle (days) | — | -44.9 | 305.7 | 476.1 | 130.5 | 19.9 | 36.8 | -588.9 | -1,279.6 | -2,100.1 |
| Receivables turnover | 6.37 | 5.30 | 4.60 | 1.82 | 1.42 | 2.51 | 2.97 | 2.64 | 2.11 | 1.24 |
| Payables turnover | — | 3.21 | 1.81 | 1.14 | 0.98 | 1.19 | 1.29 | 0.50 | 0.25 | 0.15 |
| Inventory turnover | — | — | 0.85 | 0.61 | 1.47 | 2.01 | 1.85 | — | — | — |
| Asset turnover | 0.14 | 0.13 | 0.12 | 0.11 | 0.10 | 0.10 | 0.10 | 0.09 | 0.09 | 0.11 |
| Average receivables | $121.5M | $132.8M | $140.9M | $342.6M | $400.3M | $238.5M | $225.1M | $235.7M | $192.3M | $210.0M |
| Average payables | — | $70.8M | $108.0M | $142.6M | $144.6M | $110.8M | $85.1M | $98.7M | $71.1M | $37.4M |
| Average inventory | — | — | $229.1M | $265.6M | $95.9M | $65.6M | $59.2M | — | $0 | $0 |
| Intangibles / total assets | 1.2% | 0.5% | 0.6% | 0.7% | 0.9% | 2.8% | 3.3% | 3.9% | 4.8% | 1.2% |
Computed from SBRA's annual financial statements (latest annual report filed February 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SBRA valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Sabra Health Care REIT traded at 29.8 times earnings, against a 10-year median of 27.9. Based on the latest twelve months, the trailing P/E is 77.4 and the forward P/E is 32.2. Sabra Health Care REIT earned a return on equity of 5.6% and a return on invested capital of 5.0% in fiscal 2025. It ended the year with $2.6 billion of debt and $71.5 million in cash and short-term investments, net debt of $2.5 billion. It returned $289.5 million to shareholders: $289.5 million in dividends and $0 in share buybacks, 83% of free cash flow. The share count rose 273.2% from 65.5M to 244.5M over 9 years.
See the SBRA income statement, the SBRA chart for price history, or the SBRA stock overview for the latest quote and news.
SBRA key metrics FAQ
What is Sabra Health Care REIT's P/E ratio?
Sabra Health Care REIT's trailing P/E ratio is 77.4 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 32.2. At the end of fiscal 2025 it was 29.8, compared with a 10-year median of 27.9.
What is Sabra Health Care REIT's EV/EBITDA?
Sabra Health Care REIT's enterprise value was 15.6 times EBITDA at the end of fiscal 2025 (enterprise value $7.1 billion, EBITDA $456.8 million); the current EV/EBITDA is 18.9.
What is Sabra Health Care REIT's return on equity?
Sabra Health Care REIT's return on equity (ROE) was 5.6% in fiscal 2025: net income of $155.6 million on average shareholders' equity of $2.8 billion.
What is Sabra Health Care REIT's ROIC?
Sabra Health Care REIT's return on invested capital was 5.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Sabra Health Care REIT have?
Sabra Health Care REIT had total debt of $2.6 billion at the end of fiscal 2025, a debt-to-equity ratio of 0.90 and $2.5 billion of net debt (5.43 times EBITDA).
What is Sabra Health Care REIT's dividend yield?
Sabra Health Care REIT's forward dividend yield is 6.20%. Sabra Health Care REIT paid $289.5 million in dividends in fiscal 2025 ($1.18 per share), a payout ratio of 186.0%.
What is Sabra Health Care REIT's free cash flow yield?
Sabra Health Care REIT generated $348.6 million of free cash flow in fiscal 2025, a free cash flow yield of 7.5% on its market value at year-end ($4.6 billion).
What is Sabra Health Care REIT's current ratio?
Sabra Health Care REIT's current ratio was 0.56 at the end of fiscal 2025: current assets were 0.56 times current liabilities.